Granules India enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
20,826————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
880880466381292
1,3381,3381,2861,2231,059
21,284————
458458820842767
₹858.93————
6,4236,4235,0014,4493,894
20.8%20.8%25.7%27.5%27.2%
0.06×————
3.78×————
16.66×————
21.93×————
90.56×————
Reference items — trailing FY values
5,6325,3664,4824,5064,512
1,2771,185945856914
970889720649729
—793867439739
23523529558.8328
—20627032.2315
—558572381411
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GRANULES₹840.45

Granules India Ltd.

· Pharma & Health
₹ CrorePeersAUROPHARMAIPCALABAARTIDRUGSERISINDGNEMCUREJUBLPHARMACONCORDBIOMcap ₹20,826 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————20,826.4
- Cash, Equiv & ST Investments291.6381.1466.1880.2880.2
+ Total Debt1,058.61,223.21,285.81,338.11,338.1
Enterprise Value————21,284.2
Net Debt (memo)767.1842.1819.7457.9457.9
EV per Share————858.93
Total Capital3,893.54,448.85,001.46,423.16,423.1
Total Debt/Total Capital27.1927.5025.7120.8320.83
Total Debt/EV————0.06
EV/Sales————3.78
EV/EBITDA————16.66
EV/EBIT————21.93
EV/Free Cash Flow————90.56
Reference Items — Trailing FY Values
Sales4,511.94,506.44,481.65,365.65,632.3
EBITDA913.8856.0945.21,185.11,277.3
EBIT729.3648.6719.7889.0970.4
Operating Cash Flow738.7439.4866.6793.3—
Free Cash Flow328.158.8294.9235.0235.0
FCFF (free cash flow to the firm)314.832.2270.0205.9—
Capital Expenditure410.7380.6571.7558.2—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.